Research: Treatment A.I.




The Biggest AI Winners Haven’t Arrived Yet…

This $4.3 Trillion Industry Could Deliver Them As Soon As This Year

While Nvidia, OpenAI, and Microsoft have been getting all the headlines…

Behind the scenes, start-ups like (CSE:TRUE, OTC:TREIF) have quietly been revolutionizing the multi-trillion dollar healthcare industry.

This year, their work leaves the lab and enters the marketplace…
Creating the most massive AI opportunity yet.

In the past year, Nvidia has tripled in size.

As the premier manufacturer of the GPU computer chips that power most AI systems, it is perhaps the biggest winner of the early AI race.

But don’t let the talking heads fool you — it is only the first winner, not the last.

OpenAI made headlines again as it unveiled its newest ChatGPT version, which now can easily pass the Turing Test — a test designed to see if humans could tell the difference between machine and man.

As a private company, you can’t invest in OpenAI… but many consider it the premier AI company.

In 2019, it was valued at $1 billion.

Today, it’s estimated to be worth $29 to $32 billion… with Microsoft alone already investing over $11 billion.

Wall Street analysts lament that, if you haven’t already invested in AI through companies like OpenAI, you’ve already missed the boat.

But it is the analysts who aren’t seeing the full picture.
That’s because AI is only just getting started.

As a brand-new technology, it is expanding industry by industry — just as the internet did in its early days.

And just as internet companies experienced multiple periods of accelerated growth, as it affected valuable sectors…

So too will AI.

Today, the first major sector of the economy is on the cusp of its AI revolution.

Healthcare is over 18% of the US GDP, and is worth $4.3 trillion in America alone.

And a few innovative microcaps are in position to grab an enormous chunk of that pie.

The opportunity is there, with the US healthcare system in dire need of revamping.

The technology — as you’ll see in a moment — is ready.

It won’t replace your doctors — it will just make them all better at their jobs, improving patient outcomes while cutting back on waste.

The only question now is, which companies will emerge the biggest winners, as our healthcare sector undergoes its biggest revolution since anesthetics.

The early leaders — like (CSE:TRUE, OTC:TREIF) hold the most enviable positions, with the chance to make OpenAI’s five-year 18x growth look like a small prelude.

But to understand why this is the case — and why healthcare is likely to produce the biggest AI winners yet — you need to understand why the medical field is so primed for massive improvement, thanks to AI.

Symbol:  (CSE: TRUE)  (OTCQB: TREIF) 
Company: Treatment AI


Groundbreaking Healthcare A.I. Pushes Sector Growth

But it won’t be large-language-models (LLM) that usher in a new Golden Age of medical treatment. It will be specialized models that dominate this market — like AI Inc. (CSE:TRUE, OTC:TREIF)’s proprietary technology.

It’s a leading diagnostic AI provider in general healthcare  —  potentially as great a leap forward as ChatGPT’s platform was for LLM. Yet today, AI Inc. has a market cap barely a fifth the size of its peers.

As more partnerships with groups like the Mayo Clinic (Family Medicine Department) and Minnesota Health (University of Minnesota Medical School) are announced, that’s likely to change2.

American health is in a state of neglect. It’s not just that our life expectancy has dropped for the first time ever, hitting lows not seen in nearly two decades.3 It’s not our obesity epidemic, with rates over 40% and climbing.4

It’s not just health insurance climbing in cost every year… while it seems to cover less and less. The biggest reason America’s healthcare system is running ragged is actual neglect. For years, Medicare and insurance only paid out at a rate that allowed doctors 15 minutes to spend with patients.

The days of house calls and personalized medicine are past. And now with many doctors and nurses leaving the field… even as demand has grown… the situation has become untenable. Diagnostic decisions are now being relegated to nurses and pharmacists globally, who do not have the depth of medical knowledge as clinicians.6 Yet necessity is the mother of invention. And just as America’s healthcare system is starting to crack under its own weight.

A revolutionary new application of medical AI, through the proprietary Global Library of Medicine (GLM) has arrived to help solve many of American health’s most pressing problems.

This medical AI (GLM) can…

Treatment AI is quickly becoming the best assistant a doctor or nurse could ever ask for

Its talents already surpass humans in some areas. In fact, AI is better at diagnosing some cancers than a biopsy10 and is perpetually learning and improving. However, Treatment is further differentiating through not just relying on an LLM, they are utilizing a proprietary AI solution together with a human review by a global team of peer group of credentialled clinicians. Thus, delivering a curated and accurate AI solution, which is perpetually reviewed and updated.

It can help eliminate the paperwork and busy work that eats up so much time of our valuable medical professionals’ time, without compromising the quality of support for patients. And today, you can invest in this medical AI a pioneer in this field, AI Inc. (CSE: TRUE, OTC: TREIF). The company has created the proprietary Global Library of Medicine (GLM) model that powers its AI platform and revolutionizes accurate diagnostic support for healthcare professionals. A sector that is expected to be worth $188 billion by 2030, up from $11 billion in 2021.11

Symbol:  (CSE: TRUE)  (OTCQB: TREIF) 
Company: Treatment AI



Join our exclusive group of traders and if we don’t deliver, simply unsubscribe anytime!

How Treatment’s Medical AI Outclasses The Competition

To understand why TRUE is so well positioned to dominate, you have to understand what makes its GLM so powerful.

1. Transparency

AI hallucinations — wrong information, made-up facts, or other bits of fallacious detritus — are a major problem for LLM AIs. Not so for TRUE’s GLM medical AI. Every step of the software’s process must be documented, and easily explainable to a user. Medical records are highly personal and private, and we should have absolute control over them, and know how they are being used. TRUE’s AI makes this possible. It can show you every step of its thinking when making a diagnosis, as well — along with giving you other possibilities, including recommending the most important next steps – lab tests; x-rays; and physician exams supporting the diagnosis.

Customer Journey

2. Training

The true secret sauce of the Global Library of Medicine is that it was compiled by medical experts. was founded and is led by doctors. They are the ones who created the Library, and first seeded it with diagnostic tools and data. Today, the system has had over 10,000 reviews, is overseen by hundreds of physicians globally — all medical experts — and provides the most accurate clinical information of any medical AI out there.

Those diagnoses come from one of the world’s most intelligent personalized healthcare AI engines.

And that engine is driven by its creators — the doctors behind the screen.

Exceeding > 90% diagnostic accuracy, the GLM is more sophisticated than its competitors.

As an example, TRUE’s medical AI can take a sophisticated medical history using a patient’s natural language and use those answers to form a detailed differential of the most likely diagnosis.

TRUE utilizes several factors, including the patient’s location, age, occupation, gender, and past medical history — everything a good doctor would find out in a first exam, had they the time.

Examples include:

With TRUE’s AI on the job, they can make healthcare great again.
By freeing doctors up to dedicate more time to difficult cases,’s AI makes for a better healthcare experience for everyone. Through gaining an accurate early diagnosis, there is an opportunity for patients to mitigate unnecessary, time consuming and costly healthcare visits. While doctors have more time to deal with trickier situations requiring more attention.

The core of TRUE’s medical AI is quality, breadth and accuracy. The GLM library, with >1,000 potential diagnoses and >10,000 symptoms to watch for — is the best-in-class. Yet today, AI Inc. (CSE:TRUE, OTC:TRIEF) has a market cap around $20 million — about a fifth of its peer medical AI business Healwell AI Inc. Healwell is focused on prevention — catching diseases before they become more severe, by picking up on subtle early patterns.

That’s incredibly useful.
But TRUE’s AI could potentially be the first point of contact for every medical interaction, and a constant companion through the journey. That is obviously an even larger market opportunity. But it is only one of three uses TRUE’s AI is already fulfilling.

Symbol:  (CSE: TRUE)  (OTCQB: TREIF) 
Company: Treatment AI

Helping Patients, Providers and Educators

With a LLM subprogram running the conversation, TRUE’s AI can get all the information it or any doctor could need from patients. A >90%+ diagnostic success rate means less unnecessary wasted time, visits and costs. Once a doctor signs off on the AI’s work, a prescription could automatically be filled.

That’s the patient’s journey.
Just as important is the provider’s journey. We’ve already mentioned the time-savings that’s AI can provide doctors. Both by correctly handling simple cases quickly and efficiently… And by reducing the paperwork and general administrative drudgery that sucks both time and money from the healthcare system. What we haven’t talked about yet are the educational opportunities that TRUE’s AI is already exploring.

Working with the medical school of the University of Minnesota… the nursing school and graduate programs at the Mayo Clinic, in addition to numerous medical departments… and in discussions with 52 other organizations, 27 of which are medical schools…

TRUE’s AI is proving one of the best training tools around.

Treatment is committed to providing the best tools and support to enable the next generation of healthcare professionals to excel in practical exams such as OSCE. Why? There are 1200 medical and nursing schools and more than 220,000 students in the US alone. Equally, Treatment recognizes a global shortage of trained healthcare professionals today.

Between its ability to accurately diagnose most problems on the first try… And it’s completely transparent work, allowing students to see the thought process… TRUE’s AI is an ideal interactive study tool and guide. Not only will this make for better-educated doctors and nurses going forward, but it will make for a workforce that is completely comfortable using AI as a medical tool.

That will create a more efficient, more accurate healthcare system. But it also will help pave the way for the growth of medical AI going forward. The healthcare professionals of tomorrow will be able to use and trust the same platform through their education and into their professional career.

Top 8 Reasons Why TRUE Should Be On Your Radar

Treatment AI is an emerging player with compelling investment highlights in the A.I. Healthcare Industry AI Inc. (CSE: TRUE, OTC: TREIF) offers investors a chance to participate in both the healthcare sector — a sector that makes up 11% of our GDP — and the medical AI space, one of the fastest-growing fields around. Speak with your trusted investment advisor to see if a potential high-growth medical AI company like TRUE makes sense for your portfolio.

Symbol:  (CSE: TRUE)  (OTCQB: TREIF) 
Company: Treatment AI



Put The Bull Report to the test! Join our exclusive group of traders and if we don’t deliver, simply unsubscribe anytime!

This report is for information purposes only and is neither a solicitation or recommendation to buy nor an offer to sell securities. The Bull Report is not-a-registered-investment-advisor. The Bull Report is not a broker-dealer. Information, opinions, and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. The Bull Report accepts no liability for any losses arising from an investor’s reliance on the use of this material. Starting on Mar 15, 2024 The Bull Report has been compensated $47,000 per month for coverage of TRUE by Sunburst Capital Corp. The Bull Report and its affiliates or officers may purchase, hold, and sell shares of common stock of this stock, in the open market at any time without notice. The Bull Report will not update its purchases and sales of this stock in any future postings on The Bull Report’s websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words “may”, “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend,” ” project,” and similar expressions and variations thereof are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *The Bull Report does not set price targets on securities. Never invest in a stock discussed on this website or in this email alert unless you can afford to lose your entire investment.



[2] Corporate presentation, p. 15










The Bull Report
1910 Pacific Ave,
Suite 2000, Dallas, TX 75201 / 1.469.592.7938